Know Cancer

or
forgot password

A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade

Thank you

Trial Information

A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma


Inclusion Criteria:



- Pathological diagnosis of low-grade (indolent), B-cell, non-Hodgkin's lymphoma.

- Positive expression for CD25 of tumor cells in a lymph node biopsy as defined by
greater than 20% of malignant cells staining for CD25 by standardized
immunohistochemical assay.

- Modified Ann Arbor Stage I, II, III or IV.

- Patients must have received at least two but no more than five prior therapies. One
prior therapy must have been cytotoxic chemotherapy and one prior therapy must have
been monoclonal antibody therapy. Combination chemotherapy, including regimens used
prior to bone marrow transplantation, will count as a single therapy for purposes of
eligibility.

- Patients must have bidimensionally measurable disease.

- Patients must be 18 years of age or older.

- An ECOG performance status of 0, 1, or 2.

- Acceptable organ function defined as follows:

- absolute neutrophil count (ANC) > or = to 1,000/mm3, platelet count > or = to
50,000/mm3, Hemoglobin > or = to 8 g/dL;

- Bilirubin < or = to 1.5 times the upper limit of normal (ULN);

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < or = to
1.5 times the upper limit of normal;

- Serum creatinine <1.8mg/dL;

- Serum albumin > or = to 3.0 g/dL.

- New York Heart Association classification of I or II and no history of poorly
controlled hypertension.

- Must be free of serious concurrent illness.

- Female patients must meet the following criteria:

- If the patient is a female of childbearing potential, she must have negative
serum beta human chorionic gonadotropin (B-hCG) pregnancy test within seven days
prior to study entry and must have used an effective means of contraception or
have been sexually abstinent for at least four weeks prior to the negative serum
pregnancy test and through to study entry.

- Female patients of childbearing potential must agree to practice an effective
method of birth control during the entire treatment period and for at least
three weeks after their last treatment on protocol.

Exclusion Criteria:

- Patients with cutaneous T-cell lymphoma.

- Patients previously treated with ONTAK (DAB389lL-2) or DAB486IL-2.

- Inability to comply with protocol requirements for this study.

- Pregnant women or lactating women who are breast feeding or women planning to become
pregnant during the treatment period or three weeks after their last treatment on
protocol.

- Serious intercurrent medical illnesses or active infections requiring parenteral
antibiotics, which would interfere with the ability of the patient to carry out the
treatment program.

- Sero-positive for human immunodeficiency virus (HIV) antibody. History of ongoing
Hepatitis B or Hepatitis C infection.

- Another malignancy or history of another cancer with less than five disease-free
years (other than resected basal or squamous cell skin cancers or in situ cervical
cancer).

- Patients with a known hypersensitivity to ONTAK or any of its components: diphtheria
toxin, interleukin-2, or excipients.

- Any investigational agents within one month prior to study entry.

- Prior radiation therapy within four weeks of enrollment or to the only site of
evaluable disease.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8.

Outcome Description:

Complete response: achievement of a complete regression for >4 weeks of all palpable and x-ray demonstrable disease and bone marrow disease. Partial response: response to therapy with a 75% reduction in the greatest diameters of the measurable lesions for >4 weeks and had indeterminate bone marrow biopsy

Outcome Time Frame:

24 Weeks

Safety Issue:

No

Principal Investigator

Elyane Lombardy, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Ligand Pharmaceuticals

Authority:

United States: Food and Drug Administration

Study ID:

L4389-30

NCT ID:

NCT00051025

Start Date:

May 2000

Completion Date:

September 2006

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Low-Grade
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell

Name

Location

Central Baptist HospitalLexington, Kentucky  40503
Hematology and Oncology ServicesMetairie, Louisiana  70006